Resilience Names Industry Veteran William S. Marth as CEO

• National Resilience, Inc. announced William S. Marth as its new President and Chief Executive Officer.

• Mr. Marth will build on his prior role as President and COO, furthering the company’s mission as a science-driven CDMO.

National Resilience, Inc., a technology-focused biomanufacturing company, has announced William S. Marth as its new President and Chief Executive Officer, effective immediately. Mr. Marth transitions from his previous position as Resilience’s President and Chief Operating Officer, where he oversaw the company’s development, manufacturing, and commercial activities.

In his new role, Mr. Marth will focus on strengthening the company’s customer-centric approach, ensuring high-quality execution across pre-clinical, clinical, and commercial programs. Speaking on his appointment, Mr. Marth said: “It’s an honour to assume the role of CEO at Resilience. We will continue to innovate as a science-driven CDMO, leveraging existing technologies to develop targeted solutions that address our customers’ evolving needs.”

With extensive leadership experience, Mr. Marth previously served as CEO of AMRI (now Curia Global, Inc.), where he led the company’s $1.65 billion sale to Carlyle and GTCR in 2017. Additionally, he held senior leadership roles at Teva Pharmaceuticals, overseeing operations in the Americas.

National Resilience’s focus on advanced biomanufacturing technologies aligns with Mr. Marth’s vision to drive innovation and meet the evolving demands of the biopharmaceutical sector. The company aims to enhance its position as a reliable partner for contract manufacturing.